Therapy Optimization in Population Dynamics Models
暂无分享,去创建一个
Andrzej Świerniak | Krzysztof Puszynski | Jaroslaw Smieja | Krzysztof Psiuk-Maksymowicz | Marek Kimmel | A. Świerniak | J. Śmieja | M. Kimmel | K. Psiuk-Maksymowicz | K. Puszyński
[1] A. Perelson,et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.
[2] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[3] Laurence Zitvogel,et al. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors , 2014, Oncoimmunology.
[4] Urszula Ledzewicz,et al. Minimizing Tumor Volume for a Mathematical Model of Anti-Angiogenesis with Linear Pharmacokinetics , 2010 .
[5] Antoni Ribas,et al. Tumor immunotherapy directed at PD-1. , 2012, The New England journal of medicine.
[6] D. Earn,et al. Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models , 2011, Bulletin of mathematical biology.
[7] T. Malthus. Essay on the Principle of Population , 2001 .
[8] A. Goldhirsch,et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Marek Bodnar,et al. Time delay in necrotic core formation. , 2005, Mathematical biosciences and engineering : MBE.
[10] L. Wein,et al. Optimal scheduling of radiotherapy and angiogenic inhibitors , 2003, Bulletin of mathematical biology.
[11] Pamela F. Jones,et al. The foundations of a unified approach to mathematical modelling of angiogenesis , 2009 .
[12] S. Lakshminarayanan,et al. Optimization of chemotherapy and immunotherapy: In silico analysis using pharmacokinetic–pharmacodynamic and tumor growth models , 2013 .
[13] Andrzej Świerniak. Comparison of six models of antiangiogenic therapy , 2009 .
[14] J. Folkman,et al. Angiogenesis Inhibitors Generated by Tumors , 1995, Molecular medicine.
[15] Urszula Ledzewicz,et al. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.
[16] J. Klamka. Controllability of dynamical systems , 1991, Mathematica Applicanda.
[17] Andrzej Swierniak,et al. Comparison of Simple Models of Periodic Protocols for Combined Anticancer Therapy , 2013, Comput. Math. Methods Medicine.
[18] Eugenia Corvera Poiré,et al. Tumor Angiogenesis and Vascular Patterning: A Mathematical Model , 2011, PloS one.
[19] D A Lauffenburger,et al. Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis. , 1991, Journal of theoretical biology.
[20] J. Denekamp,et al. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy , 1993 .
[21] Alberto Gandolfi,et al. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.
[22] H. Schättler,et al. On optimal delivery of combination therapy for tumors. , 2009, Mathematical biosciences.
[23] Jerzy Klamka,et al. Local Controllability of Models of Combined Anticancer Therapy with Delays in Control , 2014 .
[24] Jaroslaw Smieja,et al. Singularity of Optimal Antiangiogenic Strategies - Exception or Rule , 2010 .
[25] Andrzej Swierniak,et al. Periodic control in antiangiogenic and combined anticancer therapies , 2010, PSYCO.
[26] Robert Preissner,et al. Theoretical Modeling Techniques and Their Impact on Tumor Immunology , 2010, Clinical & developmental immunology.
[27] Peteris Daugulis,et al. Hopf point analysis for angiogenesis models , 2003 .
[28] Dmitry I. Gabrilovich,et al. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer , 2013, Cancer Immunology, Immunotherapy.
[29] Yuri Kogan,et al. Critical-point analysis for three-variable cancer angiogenesis models. , 2005, Mathematical biosciences and engineering : MBE.
[30] Yuri Kogan,et al. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics , 2008, Cancer Immunology, Immunotherapy.
[31] Thomas B. L. Kirkwood,et al. Deciphering death: a commentary on Gompertz (1825) ‘On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies’ , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[32] Urszula Ledzewicz,et al. On the Optimality of Singular Controls for a Class of Mathematical Models for Tumor Anti-Angiogenesis , 2009 .
[33] Michael Kalos,et al. T cell-based gene therapy of cancer. , 2013, Translational research : the journal of laboratory and clinical medicine.
[34] Urszula Ledzewicz,et al. AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..
[35] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[36] Z. Agur,et al. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth , 2004, Angiogenesis.
[37] M Gyllenberg,et al. Quiescence as an explanation of Gompertzian tumor growth. , 1989, Growth, development, and aging : GDA.
[38] Urszula Foryś,et al. Analysis of the Hopf bifurcation for the family of angiogenesis models , 2011 .
[39] Ricky T. Tong,et al. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.
[40] G. Yancopoulos,et al. The angiopoietins: Yin and Yang in angiogenesis. , 1999, Current topics in microbiology and immunology.
[41] N. Weidner. Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.
[42] A K LAIRD,et al. Cell fractionation of normal and malignant tissues. , 1954, Experimental cell research.
[43] J. Pinilla-Ibarz,et al. Developing strategies in the immunotherapy of leukemias. , 2013, Cancer control : journal of the Moffitt Cancer Center.
[44] Alberto Gandolfi,et al. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. , 2008, Mathematical medicine and biology : a journal of the IMA.
[45] M. Chaplain,et al. Continuous and discrete mathematical models of tumor-induced angiogenesis , 1998, Bulletin of mathematical biology.
[46] M J Plank,et al. A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies. , 2003, Mathematical medicine and biology : a journal of the IMA.
[47] J. Folkman,et al. Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.
[48] B. Teicher,et al. Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions , 2005 .
[49] Jerzy Klamka,et al. Controllability of a model of combined anticancer therapy , 2013 .
[50] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[51] Judah Folkman,et al. Thalidomide is an inhibitor of angiogenesis. , 1994 .
[52] Andrzej Swierniak,et al. Control Theory Approach to Cancer Chemotherapy: Benefiting from Phase Dependence and Overcoming Drug Resistance , 2006 .
[53] D. Yu,et al. Advances in Combination of Antiangiogenic Agents Targeting VEGF‐binding and Conventional Chemotherapy and Radiation for Cancer Treatment , 2010, Journal of the Chinese Medical Association : JCMA.
[54] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[55] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[56] Urszula Ledzewicz,et al. Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. , 2010, Mathematical medicine and biology : a journal of the IMA.
[57] Judah Folkman,et al. Angiogenesis in vitro , 1980, Nature.
[58] Helen M. Byrne,et al. 20 Mathematical modelling of angiogenesis and vascular adaptation1 , 2005 .
[59] Shay Soker,et al. VEGF/VPF: The angiogenesis factor found? , 1993, Current Biology.
[60] H. Othmer,et al. Mathematical modeling of tumor-induced angiogenesis , 2004, Journal of mathematical biology.
[61] R. Kerbel. Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.
[62] M. Essand,et al. Genetically engineered T cells for the treatment of cancer , 2013, Journal of internal medicine.
[63] A. Świerniak,et al. Direct and indirect control of cancer populations , 2008 .
[64] F Castiglione,et al. Cancer immunotherapy, mathematical modeling and optimal control. , 2007, Journal of theoretical biology.
[65] David J. Waxman,et al. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment , 2008, Molecular Cancer Therapeutics.
[66] Dirk Hasenclever,et al. Modelling Lymphoma Therapy and Outcome , 2014, Bulletin of mathematical biology.
[67] Laurence Zitvogel,et al. Immunotherapy and the concept of a clinical cure. , 2013, European journal of cancer.
[68] J. Bischoff,et al. Approaches to studying cell adhesion molecules in angiogenesis. , 1995, Trends in cell biology.
[69] Jung-Han Kimn,et al. Optimization of Virotherapy for Cancer , 2010, Bulletin of mathematical biology.
[70] A. Radunskaya,et al. Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .
[71] Xiaoming Zheng,et al. A Cell-based Model of Endothelial Cell Migration, Proliferation and Maturation During Corneal Angiogenesis , 2010, Bulletin of mathematical biology.
[72] R. Kerbel. A cancer therapy resistant to resistance , 1997, Nature.
[73] Yi Jiang,et al. A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. , 2007, Biophysical journal.
[74] Urszula Foryś,et al. ANGIOGENESIS MODEL WITH CARRYING CAPACITY DEPENDING ON VESSEL DENSITY , 2009 .
[75] Alberto Gandolfi,et al. Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular "pruning". , 2010, Journal of theoretical biology.
[76] Jonathan Dushoff,et al. Multi-Stability and Multi-Instability Phenomena in a Mathematical Model of Tumor-Immune-Virus Interactions , 2011, Bulletin of mathematical biology.
[77] M. Malisoff,et al. Constructions of Strict Lyapunov Functions , 2009 .
[78] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[79] S. McDougall,et al. Mathematical modelling of flow through vascular networks: Implications for tumour-induced angiogenesis and chemotherapy strategies , 2002, Bulletin of mathematical biology.